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Table 1
Patient Characteristics
N
Total eligible for analysis 322
Center
FHCRC 264
VAPSHCC 58
Median Range
Age (years) 50 20-75
Distant Traveled to Transplant
Center (miles)
144.95 0-2719
# Prior Chemo Regimens
2 0-9
%
Marital Status
Married 68.3
Other 31.7
Abstracts / Biol Blood Marrow Transplant 20 (2014) S57eS71S66with provider-assessed KPS90, 21 (33%) were dependent in
one or more IADL, and 14 (22%) had ADL scores 50, the
lowest quartile of the group as a whole. Similarly, in
the subset of 35 patients with HCTCI scores 0-2, 13 (37%)
were dependent in one or more IADL and 10 (29%) had ADL
scores 50.
Conclusions: CGA revealed a number of functional impair-
ments in a population of older patients deemed “ﬁt” for HCT.
In subsets of patients with provider-assessed KPS 90 or
HCTCI 0-2, one quarter to one third had quantiﬁable limita-
tions in ADL/IADL. As this study continues to accrue, we will
investigate the association between CGA measures and post-
HCT outcomes, including serial CGA post-HCT, and whether
such associations are independent of traditional prognostic
factors.Histology
Aggressive NHL 61.8
Indolent NHL 13.8
HD 23.6
Unknown <1
Conditioning Regimen
TBI-based 40
Chemotherapy-based 45
Radio-immunotherapy based 15
Chemosensitive disease?
Y 46.6
N 53.4
HCT-CI score
0 30.2
1 or 2 34.5
>3 35.4
LDH elevated?
Y 54
N 44
Unknown 2
Tobacco Use (pack years)
Never 45.3
<15 13
15-29 11
>30 14.6
Unknown 16.1
Alcohol Disorder History
Y 12.4
N 87.6
History of Drug Use
Y 20
N 80
Figure 1. NRM stratiﬁed by the presence of 0, 1 or 2+ of the following:
LDH>ULN, HCT-CI  3, alcohol disorder66
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Little is known about the impact of patient (pt)-speciﬁc
variables in risk-stratiﬁcation prior to autologous HCT for
lymphoma. We investigated the extent to which pt-related
factors other than age, namely comorbidities, alcohol use
disorders, and other demographics impact non-relapse
(NRM) after autologous HCT for lymphoma.
We retrospectively analyzed data from 322 pts treated with
autologous HCT for lymphoma between 2000 and 2005 at
the FHCRC (n¼264) and VAPSHCS (n¼58). Comorbidities
were assessed per the HCT comorbidity index (CI). Alcohol
use disorders included self-identiﬁcation as a current or past
alcoholic, engaging in current or prior “heavy” or “binge”
drinking, convictions for alcohol related crimes, or history of
rehabilitation for alcoholism.
Pre-transplant pt characteristics (Table) were assessed for
associations with NRM in univariate analysis. Factors with a
p-value of <0.1 entered Cox proportional hazard models. In
these models, HCT-CI scores of 3 (HR¼4.52, p¼.004),
elevated LDH (HR¼2.24, p¼.02), and alcohol use disorders
(HR¼2.21, p¼.05) were associated with increases risks for
NRM. Age, histology, center, chemo-sensitivity, smoking, and
drug usewere not. Hence, a simplemodel including none (36%
of pts),1 (48%), or2 (16%) signiﬁcant risk factorswas created.
Overall, NRM incidences were 8% at 1 year and 15% at 5 years.
Pts with 0, 1, or 2 of the signiﬁcant risk factors had NRM
incidences of 2%, 8% and 20% at 1-year and 6%,16% and 28% at
5-years, respectively (Figure 1). Leading causes of death
(COD) among those dying of NRMwithin 1 year (n¼24) were
infection (33%), alveolar damage (25%) and multi-organ
failure (17%). Among those dying beyond 1-year (n¼21),
leading COD were secondary malignancy (43%), infection
(14%) and chronic comorbidities (14%).In summary, pre-transplant LDH and history of alcohol use
disorders adds to the prognostic role of the HCT-CI in risk-
assessment prior to autologous HCT for lymphomas. Age,
Abstracts / Biol Blood Marrow Transplant 20 (2014) S57eS71 S67cigarette smoking, and other demographics do not. Our
simple risk model could aid in decision-making in the clinic
and highlights areas of potential intervention to reduce NRM
following auto HCT.
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Introduction: Survivors after HCT often have musculoskel-
etal complications and symptoms. Although risk factors for
many of the musculoskeletal complications have been
deﬁned, risk factors for symptoms remain unknown.
Methods: All HCT survivors treated at the Fred Hutchinson
Cancer Research Center and living in zip codes beginning with
98 were approached and asked to complete patient reported
outcomes (PRO) and permit use of their medical records. To
reduce age-related confounding ofmusculoskeletal symptoms
associated with HCT, eligibility criteria included survivors
between ages 18-49, with myeloablative HCT for hematologic
malignancy between 5-20 years before approach and English
proﬁciency adequate to complete the PRO. Exclusion criteria
were relapse or second cancer other than basal or squamous
cell skin cancer within the previous 2 years. We used the
Muscle and Joint Measure (MJM) with subscales to evaluate
outcomes of cramps, arthralgias, myalgias and weakness. Due
to a lack of normative information, we used the mean plus 0.5
SD for each subscale as a cut point to deﬁnepatientswithmore
severe symptoms. Variables signiﬁcant at p<.10 were retained
from univariate regressions, followed by backward elimina-
tion to p<.05 level for the ﬁnal models.
Results: Of 170 eligible participants, 142 completed the PRO
(84%). A majority were male (53%) with mean age 39.5
(SD¼8.9), years post-HCT mean of 11.2 (SD¼4.6); 40%
received related allogeneic HCT, 32% unrelated, 28% autolo-
gous; 65% received TBI, 32% received bone marrow as aTable 1
Final models for multivariate logistic regressions of risk factors for
musculoskeletal symptoms
OR (95% CI) P
Cramps
Age  40 2.45 (1.1-5.5) 0.03
Katz comorbidity  2 2.42 (1.1-5.3) 0.03
Arthritis 6.71 (2.4-18.5) 0.0002
AVN 3.28 (1.2-8.8) 0.02
Arthralgia
GVHD meds now 8.68 (2.1-35.5) 0.003
Age  40 4.44 (1.6-12.2) 0.004
Arthritis 22.3 (6.9-72.7) <0.0001
Myalgia
Katz comorbidity  2 2.27 (1.1-4.8) 0.03
AVN 2.83 (1.1-7.1) 0.03
Weakness
GVHD meds now 12.4 (2.4-63.0) 0.002
AVN 3.09 (1.1-8.4) 0.03
Diabetes 6.71 (1.8-25.2) 0.005source of stem cells. For late effects potentially relevant to
musculoskeletal symptoms, 16% had taken oral immuno-
suppressants for >24 months for chronic graft versus host
disease (cGVHD), 8% were currently taking medication for
cGVHD, 8% were taking diabetes medication, 17% reported
avascular necrosis (AVN), 18% reported arthritis, and 49% had
 2 comorbid conditions. Survivors reporting symptoms of
moderate or greater intensity (>4 on 0-10 scale) and occur-
ring at least weekly were: cramps 30%, myalgias 26%, joints
22%, and weakness 20%. Table 1 deﬁnes risk factors.
Conclusions: Different risk factors predicted each of the
musculoskeletal symptoms in HCT survivors. Further
research is needed to understand mechanisms and treat-
ments for these symptoms, particularly for cramps which are
the most prevalent.LEUKEMIA
68
Outcome of Allogeneic Hematopoietic Stem Cell
Transplantation for Acute Myeloid Leukemia Patients
with Central Nervous System Involvement
Jun Aoki 1, Ken Ishiyama 2, Shuichi Taniguchi 3,
Takahiro Fukuda 4, Kazuteru Ohashi 5, Hiroyasu Ogawa 6,
Yasuo Morisima 7, Tokiko Nagamura 8, Yoshiko Atsuta 9,
Hisashi Sakamaki 1, Akiyoshi Tkami 10. 1Division of
Hematology, Tokyo Metropolitan Komagome Hospital, Tokyo,
Japan; 2Department of Hematology, Tokyo Metropolitan
Otsuka Hospital, Tokyo, Japan; 3Department of Hematology,
Toranomon Hospital, Tokyo, Japan; 4Department of Stem Cell
Transplantation, National Cancer Center Hospital, Tokyo,
Japan; 5Division of Hematology, Tokyo Metropolitan Cancer
and Infectious Diseases Center Komagome Hospital, Tokyo,
Japan; 6Hematology, Hyogo College of Medicine, Nishinomiya,
Japan; 7Division of Epidemiology and Prevention, Aichi Cancer
Center Research Institute, Aichi, Japan; 8Department of Cell
Processing and Transfusion, Institute of Medical Science,
University of Tokyo, Tokyo, Japan; 9Department of HSCT, Data
Management / Biostatistics, Nagoya University Graduate
School of Medicine, Nagoya, Japan; 10Department of
Hematology and Oncology, Kanazawa University Hospital,
Ishikawa, Japan
Introduction: Central nervous system (CNS) involvement
in adult acute myeloid leukemia (AML) occurs in 2-4% of
patients at diagnosis, and is considered to have a poor
prognosis. Therefore, CNS involvement in AML is an indi-
cator for allogeneic hematopoietic stem cell transplantation
(allo-HSCT). However, the impact of CNS involvement in
AML on the outcome of allo-HSCT remains unclear. We
performed a large-scale nationwide retrospective analysis
to elucidate the outcomes of allo-HSCT for AML with CNS
involvement.
Methods: Clinical data were collected from a registry
database of the Japan Society for Hematopoietic Cell Trans-
plantation. AML patients with CNS involvement aged
16 years or older who underwent the ﬁrst allo-HSCT between
January 2006 and December 2011were compared to the AML
patients without CNS involvement who underwent the ﬁrst
allo-HSCT in the same period. CNS diseases of these patients
were diagnosed at any time from onset to allo-HSCT. The
clinical factors affecting overall survival (OS) of AML patients
with CNS involvement were analyzed using log-rank test and
Cox proportional hazard model.
Result: There were 157 and 4911 AML patients with
and without CNS involvement, respectively. Clinical
